# To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

> **NCT03731091** · PHASE3 · COMPLETED · sponsor: **Glenmark Pharmaceuticals Ltd. India** · enrollment: 494 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%
- **DRUG:** Enstilar® foam (LEO Pharma Inc.)
- **OTHER:** Placebo of Calcipotriene/ betamethasone dipropionate topical foam

## Key facts

- **NCT ID:** NCT03731091
- **Lead sponsor:** Glenmark Pharmaceuticals Ltd. India
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-31
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731091, "To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03731091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*